{"schema":"hottub-news/story/v1","story":"st_oisedendgjk4a3yuhoaq","title":"Una nuova analisi basata su modelli conferma ulteriormente il potenziale di TECVAYLI®▼ (teclistamab) in associazione con daratumumab nel ridefinire le aspettative di sopravvivenza a lungo termine nel mieloma multiplo recidivante/refrattario trattato in prima linea","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/une-nouvelle-analyse-modelisee-renforce-le-potentiel-de-tecvayli-oisedendgj","count":3,"items":[{"id":"n_auwijsyognsekrme7qgq","seq":492839,"kind":"press_release","title":"Una nuova analisi basata su modelli conferma ulteriormente il potenziale di TECVAYLI®▼ (teclistamab) in associazione con daratumumab nel ridefinire le aspettative di sopravvivenza a lungo termine nel mieloma multiplo recidivante/refrattario trattato in prima linea","url":"https://www.globenewswire.com/news-release/2026/09/28/3370197/0/it/una-nuova-analisi-basata-su-modelli-conferma-ulteriormente-il-potenziale-di-tecvayli-teclistamab-in-associazione-con-daratumumab-nel-ridefinire-le-aspettative-di-sopravvivenza-a-lu.html","summary":"BEERSE, Belgio, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, leader mondiale nel campo del trattamento del mieloma multiplo, ha annunciato oggi nuovi dati provenienti dallo studio di Fase 3 MajesTEC-3, che dimostrano un controllo della malattia e una sopravvivenza duraturi con TECVAYLI ® (teclistamab) in associazione con daratumumab nei pazienti affetti da mieloma multiplo recidivante o refrattario (RRMM) che avevano precedentemente ricevuto da 1 a 3 linee di…","published":"2026-09-28T17:58:00Z","seen":"2026-09-28T18:02:52Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q5222113","name":"daratumumab","type":"other"},{"id":"Q467635","name":"multiple myeloma","type":"other"}],"story":"st_oisedendgjk4a3yuhoaq","category":"health","category_p":0.5600000023841858,"sentiment":"neutral","tone":0.25999999046325684,"political":0.019999999552965164},{"id":"n_hjmtw65h53dkpdtuomha","seq":492841,"kind":"press_release","title":"Eine neue modellbasierte Analyse untermauert das Potenzial von TECVAYLI®▼ (teclistamab) in Kombination mit daratumumab, die Erwartungen hinsichtlich des Langzeitüberlebens bei einem rezidivierten bzw. refraktären multiplen Myelom in frühen Behandlungslinien neu zu definieren","url":"https://www.globenewswire.com/news-release/2026/09/28/3370194/0/de/eine-neue-modellbasierte-analyse-untermauert-das-potenzial-von-tecvayli-teclistamab-in-kombination-mit-daratumumab-die-erwartungen-hinsichtlich-des-langzeit%C3%BCberlebens-bei-einem-rez.html","summary":"BEERSE, Belgien, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, ein weltweit führendes Unternehmen im Bereich des multiplen Myeloms, gab heute neue Daten aus der Phase III-Studie MajesTEC-3 bekannt, die eine anhaltende Krankheitskontrolle und Überlebenszeit unter TECVAYLI ® (teclistamab) in Kombination mit daratumumab bei Patienten mit rezidiviertem oder refraktärem multiplem Myelom (RRMM) belegen, die zuvor 1 bis 3 Therapielinien erhalten hatten.","published":"2026-09-28T17:48:00Z","seen":"2026-09-28T18:02:52Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q5222113","name":"daratumumab","type":"other"}],"story":"st_oisedendgjk4a3yuhoaq","category":"health","category_p":0.4099999964237213,"sentiment":"neutral","tone":0.18000000715255737,"political":0.019999999552965164},{"id":"n_oisedendgjk4a3yuhoaq","seq":487820,"kind":"press_release","title":"Une nouvelle analyse modélisée renforce le potentiel de TECVAYLI®▼ (teclistamab) associé au daratumumab pour redéfinir les perspectives de survie à long terme dans le myélome multiple en rechute/réfractaire dans les premières lignes de traitement","url":"https://www.globenewswire.com/news-release/2026/09/28/3370193/0/fr/une-nouvelle-analyse-mod%C3%A9lis%C3%A9e-renforce-le-potentiel-de-tecvayli-teclistamab-associ%C3%A9-au-daratumumab-pour-red%C3%A9finir-les-perspectives-de-survie-%C3%A0-long-terme-dans-le-my%C3%A9lome-multiple-.html","summary":"BEERSE, Belgique, 28 sept. 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, leader mondial dans le domaine du myélome multiple, a annoncé aujourd’hui de nouvelles données issues de l’étude de Phase 3 MajesTEC-3, mettant en évidence un contrôle durable de la maladie et une survie prolongée avec TECVAYLI ® (teclistamab) associé au daratumumab chez des patients atteints d’un myélome multiple en rechute ou réfractaire (MMRR) ayant reçu 1 à 3 lignes de traitement antérieures.","published":"2026-09-28T17:44:00Z","seen":"2026-09-28T17:47:20Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q5222113","name":"daratumumab","type":"other"}],"story":"st_oisedendgjk4a3yuhoaq","category":"health","category_p":0.4699999988079071,"sentiment":"neutral","tone":0.18000000715255737,"political":0.019999999552965164}]}